Page last updated: 2024-11-04

semustine and Melanoma

semustine has been researched along with Melanoma in 44 studies

Semustine: 4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.
semustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group.

Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)

Research Excerpts

ExcerptRelevanceReference
"One hundred and fifty-seven evaluable patients with advanced metastatic malignant melanoma were randomly assigned to receive either methyl-CCNU (MeCCNU) (200 mg/m2 orally every 6 weeks) (82 patients) or a combination of MeCCNU, chlorpromazine (50 mg/m2 im), and caffeine (600 mg/m2 sc) in the periumbilical area (75 patients)."9.05Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma. ( Cohen, MH; Schoenfeld, D; Wolter, J, 1980)
"The nephrotoxicity of semustine (methyl-CCNU) has been studied in 45 adult patients with surgically resected Stage I or II malignant melanoma who received this drug as adjuvant chemotherapy."9.05Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. ( Fisher, RI; Jensen-Akula, M; Mandard, JC; Micetich, KC, 1981)
"Patients with advanced malignant melanoma were randomly assigned to treatment with cylcophosphamide and vincristine (CV) or cyclophosphamide, vincristine, and procarbazine (CVP)."9.04Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma. ( Byrne, MJ, 1976)
"One hundred twenty-two patients with disseminated malignant melanoma were randomized using an unbalanced randomization to receive chlorozotocin, neocarzinostatin, or MeCCNU."7.67Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma. ( Amato, DA; Cunningham, TJ; Falkson, G; Kaufman, JH; Von Hoff, DD, 1984)
"Cells from a resistant ("Gr II") and a sensitive ("Str") human melanoma xenograft were incubated in vitro with O6-methylguanine for 2 h, subsequently treated with 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea (MeCCNU) for 1 h and then plated in soft agar."7.67Increased cytotoxicity of 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea by pretreatment with O6-methylguanine in resistant but not in sensitive human melanoma cells. ( Dempke, W; Nehls, P; Osieka, R; Schmidt, CG; Soll, D; Wandl, U, 1987)
"In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma."7.67Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma. ( Amato, DA; Ash, A; Borden, EC; Bruckner, H; Creech, RH; Cunningham, TJ; Falkson, G; Guerry, D; Savlov, ED, 1987)
"Twenty-six patients with disseminated malignant melanoma received an oral regimen of mitolactol and semustine (methyl-CCNU)."7.66Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma. ( Ahmann, DL; Creagan, ET; Green, SJ; Schutt, AJ, 1982)
"One hundred and fifty-seven evaluable patients with advanced metastatic malignant melanoma were randomly assigned to receive either methyl-CCNU (MeCCNU) (200 mg/m2 orally every 6 weeks) (82 patients) or a combination of MeCCNU, chlorpromazine (50 mg/m2 im), and caffeine (600 mg/m2 sc) in the periumbilical area (75 patients)."5.05Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma. ( Cohen, MH; Schoenfeld, D; Wolter, J, 1980)
"The nephrotoxicity of semustine (methyl-CCNU) has been studied in 45 adult patients with surgically resected Stage I or II malignant melanoma who received this drug as adjuvant chemotherapy."5.05Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. ( Fisher, RI; Jensen-Akula, M; Mandard, JC; Micetich, KC, 1981)
"Patients with advanced malignant melanoma were randomly assigned to treatment with cylcophosphamide and vincristine (CV) or cyclophosphamide, vincristine, and procarbazine (CVP)."5.04Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma. ( Byrne, MJ, 1976)
"One hundred twenty-two patients with disseminated malignant melanoma were randomized using an unbalanced randomization to receive chlorozotocin, neocarzinostatin, or MeCCNU."3.67Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma. ( Amato, DA; Cunningham, TJ; Falkson, G; Kaufman, JH; Von Hoff, DD, 1984)
"Cells from a resistant ("Gr II") and a sensitive ("Str") human melanoma xenograft were incubated in vitro with O6-methylguanine for 2 h, subsequently treated with 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea (MeCCNU) for 1 h and then plated in soft agar."3.67Increased cytotoxicity of 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea by pretreatment with O6-methylguanine in resistant but not in sensitive human melanoma cells. ( Dempke, W; Nehls, P; Osieka, R; Schmidt, CG; Soll, D; Wandl, U, 1987)
"In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma."3.67Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma. ( Amato, DA; Ash, A; Borden, EC; Bruckner, H; Creech, RH; Cunningham, TJ; Falkson, G; Guerry, D; Savlov, ED, 1987)
"Twenty-six patients with disseminated malignant melanoma received an oral regimen of mitolactol and semustine (methyl-CCNU)."3.66Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma. ( Ahmann, DL; Creagan, ET; Green, SJ; Schutt, AJ, 1982)
"Human melanoma xenografts in immune-deprived mice have been used to assess the value of the agar diffusion chamber for chemosensitivity testing."3.66Use of the agar diffusion chamber for the exposure of human tumor cells to drugs. ( Selby, PJ; Steel, GG, 1982)
"The therapeutic usefulness of chlorpromazine (CPZ) and caffeine (CAF) in combination with selected nitrosoureas was investigated in mice bearing L1210 leukemia, Lewis lung carcinoma, and B16 melanoma."3.66Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors. ( Dykes, DJ; Laster, WR; Rose, WC; Schabel, FM; Trader, MW, 1978)
"Single doses of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea caused transient suppression of [3H]thymidine incorporation into DNA in bone marrow and gastrointestinal mucosa and more prolonged inhibition of such incorporation in B16 melanoma."3.65Inhibition and recovery of DNA synthesis in host tissues and sensitive and resistant B16 melanoma after 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea, a predictor of therapeutic efficacy. ( Brereton, HD; Bryant, TL; Young, RC, 1975)
" Further, both disease staging and drug dosage have been shown to influence cure rates of combined-modality treatment."2.35Concepts for treatment of micrometastases developed in murine systems. ( Schabel, FM, 1976)
" The results imply that dosage scheduling in the treatment of murine melanomas must be individualized."1.26Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas. ( Hill, GJ; Hill, HZ, 1982)
" Dose-response curves were obtained and the surviving fraction at drug levels estimated to be achieved in man was used as a measure of in vitro drug sensitivity."1.26In vitro chemosensitivity tests on xenografted human melanomas. ( Bateman, AE; Selby, PJ; Steel, GG; Towse, GD, 1980)

Research

Studies (44)

TimeframeStudies, this research(%)All Research%
pre-199042 (95.45)18.7374
1990's2 (4.55)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Osieka, R6
Glatte, P4
Pannenbäcker, R2
Schmidt, CG5
Von Hoff, DD1
Amato, DA2
Kaufman, JH1
Falkson, G2
Cunningham, TJ2
Kemeny, N1
Raina, S1
Hill, HZ3
Hill, GJ3
Rush, BF1
Kirkwood, JM1
Marsh, JC1
Cohen, MH1
Schoenfeld, D2
Wolter, J2
Fisher, RI2
Terry, WD1
Hodes, RJ1
Rosenberg, SA1
Makuch, R1
Gordon, HG1
Fisher, SG1
Micetich, KC1
Jensen-Akula, M1
Mandard, JC1
Knost, JA1
Reynolds, V1
Greco, FA1
Oldham, RK1
Creagan, ET1
Ahmann, DL3
Schutt, AJ1
Green, SJ1
Selby, PJ2
Steel, GG2
Haedecke, U1
Griswold, DP2
Corbett, TH1
Schabel, FM5
Bateman, AE1
Towse, GD1
Coates, AS1
Segelov, E1
Livingston, RB1
Einhorn, LH2
Bodey, GP1
Burgess, MA1
Freireich, EJ1
Gottlieb, JA1
Mabel, JA1
Merker, PC1
Sturgeon, ML1
Wodinsky, I1
Geran, RI1
Furnas, B1
Costanza, ME1
Nathanson, L1
Colsky, J1
Regelson, W1
Cunningham, T1
Sedransk, N1
Kokoschka, EM1
Luger, T1
Micksche, M1
Berd, D2
Wilson, EJ1
Bellet, RE2
Mastrangelo, MJ2
Miller, CL1
Pfaller, M1
Weiss, K1
Galin, M1
Berkelhammer, J1
Prehn, RT1
Didolkar, MS1
Baffi, RR1
Catane, R1
Kaufman, J1
Holyoke, ED1
Lee, W1
Moore, RP1
Wampler, GL1
Rose, WC1
Trader, MW1
Dykes, DJ2
Laster, WR1
Bisel, HF1
Edmonson, JH1
Hahn, RG1
Eagan, RT1
O'Connell, MJ1
Frytak, S1
Byrne, MJ1
Wittes, RE1
Hong, WK1
Gatchell, L1
Krakoff, IH1
Golbey, RB1
Brereton, HD1
Bryant, TL1
Young, RC1
Luce, JK1
Boaziz, C1
Breau, JL1
Morere, JF1
Israël, L1
Paietta, E1
Papenhausen, P1
Ciobanu, N1
Dutcher, JP1
Wiernik, PH1
Dempke, W1
Nehls, P1
Wandl, U1
Soll, D1
Bruckner, H1
Guerry, D1
Ash, A1
Borden, EC1
Creech, RH1
Savlov, ED1
Wasserman, TH1
Slavik, M1
Carter, SK1

Reviews

5 reviews available for semustine and Melanoma

ArticleYear
The systemic chemotherapy of hepatic metastases.
    Seminars in oncology, 1983, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D

1983
Concepts for treatment of micrometastases developed in murine systems.
    AJR. American journal of roentgenology, 1976, Volume: 126, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Survival; Colonic Neoplasms; Cricetinae; Cyclop

1976
Nitrosoureas: a review of experimental antitumor activity.
    Cancer treatment reports, 1976, Volume: 60, Issue:6

    Topics: Animals; Carmustine; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Resistance; Drug Therapy,

1976
[Brain metastases of malignant melanomas].
    Bulletin du cancer, 1991, Volume: 78, Issue:4

    Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Interl

1991
Methyl-CCNU inclinical cancer therapy.
    Cancer treatment reviews, 1974, Volume: 1, Issue:4

    Topics: Animals; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous

1974

Trials

12 trials available for semustine and Melanoma

ArticleYear
The systemic chemotherapy of hepatic metastases.
    Seminars in oncology, 1983, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D

1983
Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma.
    Cancer treatment reports, 1980, Volume: 64, Issue:1

    Topics: Caffeine; Chlorpromazine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Melanoma; Nit

1980
Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.
    The Surgical clinics of North America, 1981, Volume: 61, Issue:6

    Topics: BCG Vaccine; Cell Line; Clinical Trials as Topic; Female; Humans; Male; Melanoma; Mitomycins; Neopla

1981
Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy.
    The American journal of medicine, 1981, Volume: 71, Issue:6

    Topics: Adolescent; Adult; Aged; Blood Urea Nitrogen; Clinical Trials as Topic; Creatinine; Humans; Kidney;

1981
Adjuvant chemoimmunotherapy stage I/II malignant melanoma.
    Journal of surgical oncology, 1982, Volume: 19, Issue:3

    Topics: Adolescent; Adult; Aged; BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Lymph N

1982
Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
    Cancer treatment reports, 1977, Volume: 61, Issue:5

    Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Leuko

1977
Results with methyl-CCNU and DTIC in metastatic melanoma.
    Cancer, 1977, Volume: 40, Issue:3

    Topics: Brain Neoplasms; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Dacarbazine; Drug

1977
[Immuno-chemotherapy in patients with disseminated metastasizing stage III melanoma. Randomized study with methyl-CCNU versus C. parvum plus methyl-CCNU].
    Onkologie, 1978, Volume: 1, Issue:3

    Topics: Bacterial Vaccines; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compo

1978
Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients.
    European journal of cancer, 1979, Volume: 15, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Cell Line; Cytotoxicity, Immunologic; Drug Therapy,

1979
Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma.
    Clinical pharmacology and therapeutics, 1976, Volume: 19, Issue:6

    Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Administration Schedule; Drug

1976
Nitrosoureas in the management of disseminated malignant melanoma.
    Cancer treatment reports, 1976, Volume: 60, Issue:6

    Topics: Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Humans; Lomustine;

1976
Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma.
    Cancer, 1976, Volume: 38, Issue:5

    Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Fem

1976

Other Studies

28 other studies available for semustine and Melanoma

ArticleYear
Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system.
    Cancer chemotherapy and pharmacology, 1983, Volume: 11, Issue:3

    Topics: Animals; Bone Marrow; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Female; Humans;

1983
Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma.
    American journal of clinical oncology, 1984, Volume: 7, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis

1984
Studies on drug resistance in a human melanoma xenograft system.
    Cancer treatment reviews, 1984, Volume: 11 Suppl A

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Models, Ani

1984
Scheduling of combination chemotherapy for a murine melanoma, with the subrenal capsular assay.
    Journal of surgical oncology, 1984, Volume: 26, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule;

1984
In vivo drug sensitivity assay of clonogenic human melanoma cells and correlation with treatment outcome.
    Cancer research, 1983, Volume: 43, Issue:7

    Topics: Animals; Biological Assay; Biotransformation; Cell Survival; Clone Cells; Dacarbazine; Drug Evaluati

1983
Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas.
    Cancer research, 1982, Volume: 42, Issue:3

    Topics: Animals; Cell Line; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Female; Me

1982
Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma.
    Cancer treatment reports, 1982, Volume: 66, Issue:6

    Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukocyte Count; Leukopenia; Male;

1982
Use of the agar diffusion chamber for the exposure of human tumor cells to drugs.
    Cancer research, 1982, Volume: 42, Issue:11

    Topics: Agar; Animals; Antineoplastic Agents; Cell Survival; Diffusion; Doxorubicin; Drug Evaluation, Precli

1982
[Enhancement of MeCCNU potency (chemosensitization) by misonidazole in a human melanoma xenograft system].
    Strahlentherapie, 1982, Volume: 158, Issue:10

    Topics: Animals; Cell Line; Drug Interactions; Female; Humans; Melanoma; Mice; Mice, Nude; Misonidazole; Neo

1982
Clonogenicity and growth of experimental tumors in relation to developing resistance and therapeutic failure.
    Cancer treatment reports, 1981, Volume: 65 Suppl 2

    Topics: Animals; Clone Cells; Cyclophosphamide; Drug Resistance; Humans; Leukemia L1210; Melanoma; Mice; Neo

1981
In vitro chemosensitivity tests on xenografted human melanomas.
    British journal of cancer, 1980, Volume: 41, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Hu

1980
Long term response to chemotherapy in patients with visceral metastatic melanoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother

1994
COMB (cyclophosphamide, oncovin, methyl-CCNU, and bleomycin): a four-drug combination in solid tumors.
    Cancer, 1975, Volume: 36, Issue:2

    Topics: Bleomycin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Evaluation; Drug

1975
Combination chemotherapy against B16 melanoma: bleomycin/vinblastine, bleomycin/cis-diamminedichloroplatinum, 5-fluorouracil/BCNU and 5-fluorouracil/methyl-CCNU.
    Cancer, 1978, Volume: 42, Issue:4

    Topics: Animals; Antineoplastic Agents; Bleomycin; Carmustine; Cisplatin; Dose-Response Relationship, Drug;

1978
Effect of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea adjuvant therapy on the immune response of patients with malignant melanoma.
    Cancer research, 1979, Volume: 39, Issue:11

    Topics: Adult; Aged; Antibody Formation; Antigens; Dinitrochlorobenzene; Escherichia coli; Female; Hemocyani

1979
Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, and L-phenylalanine mustard on B16, Cloudman S91, and Harding-Passey mouse melanomas.
    Cancer research, 1979, Volume: 39, Issue:3

    Topics: Animals; Cell Count; Dacarbazine; Female; Melanoma; Melphalan; Mice; Mice, Inbred Strains; Neoplasm

1979
Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
    Cancer treatment reports, 1977, Volume: 61, Issue:9

    Topics: Dacarbazine; Drug Evaluation; Drug Resistance; Humans; Melanoma; Nitrosourea Compounds; Procarbazine

1977
Interstitial pulmonary fibrosis as a complication of prolonged methyl-CCNU therapy.
    Cancer treatment reports, 1978, Volume: 62, Issue:9

    Topics: Brain Neoplasms; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Pu

1978
Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors.
    Cancer treatment reports, 1978, Volume: 62, Issue:12

    Topics: Animals; Caffeine; Carmustine; Chlorpromazine; Drug Synergism; Drug Therapy, Combination; Female; Le

1978
Methyl-CCNU in malignant melanoma--a divided dose schedule of administration.
    Oncology, 1977, Volume: 34, Issue:1

    Topics: Bone Marrow; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Met

1977
Inhibition and recovery of DNA synthesis in host tissues and sensitive and resistant B16 melanoma after 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea, a predictor of therapeutic efficacy.
    Cancer research, 1975, Volume: 35, Issue:9

    Topics: Animals; Bone Marrow; Cell Division; Depression, Chemical; DNA; DNA, Neoplasm; Gastric Mucosa; Intes

1975
Chemotherapy of melanoma.
    Seminars in oncology, 1975, Volume: 2, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; D

1975
Growth support of small B16 melanoma implants with nitrosourea-sterilized fractions of the same tumor.
    Cancer research, 1976, Volume: 36, Issue:6

    Topics: Animals; Carmustine; Cell Line; Cells, Cultured; Melanoma; Mice; Neoplasm Transplantation; Neoplasms

1976
Chemosensitization by chlorpromazine (CPZ) and caffeine (C) in human melanoma xenografts sensitive or resistant to methyl-CCNU (semustine).
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1989, Volume: 165, Issue:7

    Topics: Animals; Caffeine; Chlorpromazine; Drug Resistance; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Tra

1989
Biphenotypic leukemia with unusual chromosomal translocation in a patient treated for melanoma.
    Cancer genetics and cytogenetics, 1986, Apr-15, Volume: 21, Issue:4

    Topics: Acute Disease; Adult; Antibodies, Monoclonal; Antigens, Neoplasm; Chromosomes, Human, 1-3; Histocomp

1986
Increased cytotoxicity of 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea by pretreatment with O6-methylguanine in resistant but not in sensitive human melanoma cells.
    Journal of cancer research and clinical oncology, 1987, Volume: 113, Issue:4

    Topics: Animals; Bone Marrow; Bone Marrow Cells; Cell Division; Colony-Forming Units Assay; Cross-Linking Re

1987
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma.
    Investigational new drugs, 1987, Volume: 5, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho

1987
Enhancement of semustine-induced cytotoxicity by chlorpromazine and caffeine in a human melanoma xenograft.
    Cancer treatment reports, 1986, Volume: 70, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Caffeine; Chlorpromazine; DNA

1986